1. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К., Вишнёва Е.А., Федосеенко М.В., Селимзянова Л.Р., Чемакина Д.С., Лобзин Ю.В., Харит С.М., Брико Н.И., Лопухов П.Д., Сухих Г.Т., Уварова Е.В., Прилепская В.Н., Поляков В.Г., Гомберг М.А., Краснопольский В.И., Зароченцева Н.В., Костинов М.П., Белоцерковцева Л.Д., Мельникова А.А., Батыршина Л.Р. Вакцинопрофилактика заболеваний, вызванных вирусом папилломы человека: позиции доказательной медицины. Обзор клинических рекомендаций. Вопросы современной педиатрии. 2017;16(2):107-117. DOI: 10.15690/vsp.v16i2.1711 EDN: YRGVQZ
Baranov А.А., Namazova-Baranova L.S., Tatochenko V.K., Vishneva E.A., Fedoseenko M.V., Selimzianova L.R., Chemakina D.S., Lobzin Yu.V., Kharit S.M., Briko N.I., Lopukhov P.D., Sukhikh G.T., Uvarova E.V., Prilepskaya V.N., Polyakov V.G., Gomberg M.A., Krasnopolskiy V.I., Zarochentseva N.V., Kostinov M.P., Belotserkovtseva L.D., Melnikova A.A., Batyrshina L.R. Vaccinal prevention of the diseases caused by human papillomavirus: evidence-based medicine. Review of clinical guidelines. Voprosy Sovremennoy Pediatrii = Current Pediatrics. 2017;16(2):107-117. 10.15690/vsp.v16i2.1711 (in Russian). DOI: 10.15690/vsp.v16i2.1711(inRussian)
2. Зильбер Л.А. Вирусо-генетическая теория возникновения опухолей. М.: Наука, 1968.
Silber L.A. The Virogenetic Theory of the Occurrence of Tumors. Moscow: Nauka Publ., 1968 (in Russian).
3. Каледин В.И. К вопросу о сущности изменений, лежащих в основе опухолевого роста. В: IV Всесоюзный съезд онкологов. Тезисы докладов. Ленинград, 1986;468-470.
Kaledin V.I. On the question of the essence of the changes underlying tumor growth. In: IV All-Union Congress of Oncologists. Abstracts of Reports. Leningrad, 1986;468-470 (in Russian).
4. Каледин В.И. Канцерогенез: новая - старая - парадигма. В: I международная мультидисциплинарная конференция “Актуальные проблемы науки XXI века”. Часть 1. М.: Cognitio, 2015;5-10.
Kaledin V.I. Carcinogenesis: a new - the old - paradigm. In: I World Multidisciplinary Conference “Current Problems of Science of the 21st Century”. Мoscow: Cognitio, 2015;5-10 (in Russian).
5. Каледин В.И., Николин В.П., Попова Н.А. Индукция апоптоза как условие радикализации химиотерапии опухолей. Письма в Вавиловский журнал. 2018;4(1):1-7. EDN: MEBRWY
Kaledin V.I., Nikolin V.P., Popova N.A. Induction of apoptosis as a possible mean for radicalization of cancer chemotherapy. Pisma v Vavilovskii Zhurnal. 2018;4(1):1-7 (in Russian). EDN: MEBRWY
6. Любченко Л.Н., Батенева Е.И., Воротников И.К., Портной С.М., Крохина О.В., Соболевский В.А., Жукова Л.Г., Хайденко В.А., Тюляндин С.А. Наследственный рак молочной железы: генетическая и клиническая гетерогенность, молекулярная диагностика, хирургическая профилактика в группах риска. Успехи молекулярной онкологии. 2014;(2):16-24. EDN: TRRYOX
Lyubchenko L.N., Bateneva E.I., Vorotnikov I.K., Portnoy S.M., Krokhina O.V., Sobolevskiy V.A., Zhukova L.G., Khaylenko V.A., Tyulyandin S.A. Hereditary breast cancer: genetic and clinical hetergeneity, genetic testing, prophylactic surgery. Uspekhi Molekulyarnoy Onkologii = Advances in Molecular Oncology. 2014;(2):16-24 (in Russian). EDN: TRRYOX
7. Майборода А.А. Гены и белки онкогенеза. Сибирский медицинский журнал. 2013;(2):132-138. EDN: QBSQUD
Mayboroda A.A. Genes and proteins of carcinogenesis. Sibirskiy Meditsinskiy Zhurnal = Siberian Scientific Medical Journal. 2013;(2):132-138 (in Russian). EDN: QBSQUD
8. Мустафин Р.Н., Хуснутдинова Э.К. Эпигенетика канцерогенеза. Креативная хирургия и онкология. 2017;7(3):60-64. DOI: 10.24060/2076-3093-2017-7-3-60-67 EDN: ZHEOHH
Mustafin R.N., Khusnutdinova E.K. Epigenetics of carcinogenesis. Kreativnaya Khirurgiya i Onkologiya = Creative Surgery and Oncology. 2017;7(3):60-64. 10.24060/2076-3093-2017-7-3-60-67 (in Russian). DOI: 10.24060/2076-3093-2017-7-3-60-67(inRussian) EDN: ZHEOHH
9. Николин В.П., Каледин В.И., Баймак Т.Ю., Галямова М.Р., Попова Н.А., Войцицкий В.Е. Апоптоз-индуцированная и противоопухолевая эффективность циклофосфана, платина и адриомицина при их раздельном применении и в комбинации у мышей с лимфосаркомой LS. Вопросы онкологии. 2002;48(2):211-215. EDN: MPKFSJ
Nikolin V.P., Kaledin V.I., Baĭmak T.Iu., Galiamova M.R., Popova N.A., Voĭtsitskiĭ V.E. Apoptosis-inducing and anti-tumor effect of cyclophosphamide, cisplatin and adriamycin used separately or combined in murine lymphosarcoma LS. Voprosy Onkologii = Problems in Oncology. 2002;48(2):211-215 (in Russian). EDN: MPKFSJ
10. Balmain A., Harris C.C. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis. 2000;21(3):371-377. DOI: 10.1093/carcin/21.3.371 EDN: IMWDXV
11. Barnes J.L., Zubair M., John K., Poirier M.C., Martin F.L. Carcinogens and DNA damage. Biochem. Soc. Trans. 2018;46(5):1213-1224. DOI: 10.1042/BST20180519
12. Baudi F. Hereditary tumours. Biomed. Res. Int. 2013;2013:490357. DOI: 10.1155/2013/490357
13. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer. 2011;11(10):726-734. DOI: 10.1038/nrc3130 EDN: PHWTER
14. Bouck N., Kokkinakis D., Ostrowsky J. Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine. Mol. Cell. Biol. 1984;4(7):1231-1237. DOI: 10.1128/mcb.4.7.1231-1237.1984
15. Breasted J.N. The Edwin Smith Papirus: Some Preliminapy Observations. Librairie Ancienne Honoré Champion, Edward Champion, 1922.
16. Butera A., Melino G., Amelio I. Epigenetic “Drivers” of cancer. J. Mol. Biol. 2021;433(15):167094. DOI: 10.1016/j.jmb.2021.167094 EDN: AWHMBS
17. Caserta S., Gangemi S., Murdaca G., Allegra A. Gender differences and mirnas expression in cancer: implications on prognosis and susceptibility. Int. J. Mol. Sci. 2023;24(14):11544. DOI: 10.3390/ijms241411544 EDN: MMFDVM
18. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27. DOI: 10.1016/j.cell.2012.06.013 EDN: RIBVZR
19. Epstein M.A., Achong B.G., Barr Y.M. Virus parnicles in cultured lymphoblasts from Burkitts lymphoma. Lancet. 1964;1(7335):702-703. DOI: 10.1016/s0140-6736(64)91524-7
20. Flanagan J.M. Host epigenetic modifications by oncogenic viruses. Br. J. Cancer. 2007;96(2):183-188. DOI: 10.1038/sj.bjc.6603516 EDN: XADOBK
21. Flotho C., Claus R., Batz C., Schneider M., Sandrock I., Ihde S., Plass C., Niemeyer C.M., Lübbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;(6):1019-1028. DOI: 10.1038/leu.2008.397
22. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell. 2013;153(1):17-37. DOI: 10.1016/j.cell.2013.03.002 EDN: RHGENH
23. Gim J., Ha H., Ahn K., Kim D.S., Kim H.S. Genomewide identification and classification of microRNAs derived from repetitive elements. Genomics Inform. 2014;12(4):261-267. DOI: 10.5808/GI.2014.12.4.261
24. Iranzo J., Martincorena I., Koonin E.V. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl. Acad. Sci. USA. 2018;115(26):E6010-E6019. DOI: 10.1073/pnas.1803155115 EDN: YKDDUL
25. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002;3(6):415-428. DOI: 10.1038/nrg816
26. Karaman E.F., Abudayyak M., Ozden S. The role of chromatin-modifying enzymes and histone modifications in the modulation of p16 gene in fumonisin B1-induced toxicity in human kidney cells. Mycotoxin Res. 2023;39(3):271-283. DOI: 10.1007/s12550-023-00494-2 EDN: CFDBXF
27. Karlic H., Herrmann H., Varga F., Thaler R., Reitermaier R., Spitzer S., Ghanim V., Blatt K., Sperr W.R., Valent P., Pfeilstöcker M. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 2014;90(1):1-16. DOI: 10.1016/j.critrevonc.2013.10.003 EDN: USKKRT
28. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 1971;68(4):820-823. DOI: 10.1073/pnas.68.4.820
29. Ledford H. End of cancer-genome project prompts rethink. Nature. 2015;517(7533):128-129. DOI: 10.1038/517128a
30. Li E., Zhang Y. DNA methylation in mammals. Cold Spring Harb. Perspect. Biol. 2014;6(5):a019133. DOI: 10.1101/cshperspect.a019133
31. MacLennan S.A., Marra M.A. Oncogenic viruses and the epigenome: how viruses hijack epigenetic mechanisms to drive cancer. Int. J. Mol. Sci. 2023;24(11):9543. DOI: 10.3390/ijms24119543 EDN: QCHBRC
32. MacLeod M.C. A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. Mol. Carcinog. 1996;15(4):241-250. :4<241:AID-MC1>3.0.CO;2-J. DOI: 10.1002/(SICI)1098-2744(199604)15
33. Miller E.C. Some current perspectives on chemical carcinogenesis in humans and experimental animals: presidential address. Cancer Res. 1978;38(6):1479-1496.
34. Miller E.C., Miller J.A. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer. 1981;47(10):2327-2345. :10<2327::aid-cncr2820471003>3.0.co;2-z. DOI: 10.1002/1097-0142(19810515)47
35. Miranda Furtado C.L., Dos Santos Luciano M.C., Silva Santos R.D., Furtado G.P., Moraes M.O., Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14(12):1164-1176. DOI: 10.1080/15592294.2019.1640546 EDN: JNTGXK
36. Murashko M.M., Stasevich E.M., Schwartz A.M., Kuprash D.V., Uvarova A.N., Demin D.E. The role of RNA in DNA breaks, repair and chromosomal rearrangements. Biomolecules. 2021;11(4):550. DOI: 10.3390/biom11040550 EDN: QUFQJO
37. Murphy S.A., Mapes N.J. Jr., Dua D., Kaur B. Histone modifiers at the crossroads of oncolytic and oncogenic viruses. Mol. Ther. 2022;30(6):2153-2162. DOI: 10.1016/j.ymthe.2022.02.006 EDN: HATMTZ
38. Navada S.C., Steinmann J., Lübbert M., Silverman L.R. Clinical development of demethylating agents in hematology. J. Clin. Invest. 2014;124(1):40-46. DOI: 10.1172/JCI69739
39. Ponnusamy L., Mahalingaiah P.K.S., Chang Y.W., Singh K.P. Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. Cancer Drug. Resist. 2019;2(2):297-312. DOI: 10.20517/cdr.2018.11 EDN: NVFORU
40. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005;6(8):597-610. DOI: 10.1038/nrg1655
41. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 1911;13(4):397-411. DOI: 10.1084/jem.13.4.397
42. Samantarrai D., Dash S., Chhetri B., Mallick B. Genomic and epigenomic cross-talks in the regulatory landscape of miRNAs in breast cancer. Mol. Cancer Res. 2013;11(4):315-328. DOI: 10.1158/1541-7786 EDN: YDHUDH
43. Sanaei M., Kavoosi F. Effect of zebularine on apoptotic pathways in hepatocellular carcinoma cell lines. Int. J. Prev. Med. 2023;14:63. DOI: 10.4103/ijpvm.ijpvm_191_21 EDN: WZVBPJ
44. Schiller J.T., Lowy D.R. An introduction to virus infections and human cancer. Recent Results Cancer Res. 2021;217:1-11. DOI: 10.1007/978-3-030-57362-1 EDN: DLFFAL
45. Sonawala K., Ramalingam S., Sellamuthu I. Influence of long non-coding RNA in the regulation of cancer stem cell signaling pathways. Cells. 2022;11(21):3492. DOI: 10.3390/cells11213492 EDN: DIDBKS
46. Soto A.M., Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm? BioEssays. 2004;26(10):1097-1107. DOI: 10.1002/bies.20087
47. Vrba L., Muñoz-Rodríguez J.L., Stampfer M.R., Futscher B.W. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One. 2013;8(1):e54398. DOI: 10.1371/journal.pone.0054398
48. Wang G.G., Allis C.D., Chi P. Chromatin remodeling and cancer. Part I: Covalent histone modifications. Trends Mol. Med. 2007a;13(9):363-372. DOI: 10.1016/j.molmed.2007.07.003
49. Wang G.G., Allis C.D., Chi P. Chromatin remodeling and cancer. Part II: ATP-dependent chromatin remodeling. Trends Mol. Med. 2007b;13(9):373-380. DOI: 10.1016/j.molmed.2007.07.004
50. Zeiger E. Mutagens that are not carcinogens: faulty theory or faulty tests? Mutat. Res. 2001;492(1-2):29-38. 10.1016/s1383-5718(01)00153-x. Erratum in: Mutat. Res. 2001;498(1-2):219. DOI: 10.1016/s1383-5718(01)00153-x.Erratumin EDN: ANKFLF